Skip to main content
. 2016 Sep 14;6:33072. doi: 10.1038/srep33072

Figure 5.

Figure 5

Effects of 72-h pre-incubation with CYP3A4/SLCO1B1 inducers (phenobarbital, PB and rifampicin, Rif) or 24-h co-incubation with CYP3A4 inhibitor (ketoconazole, Ket), SLCO1B1 inhibitors (gemfibrozil, Gem and rifampicin, Rif) on atorvastatin hepatotoxicity (a) and ROS generation (b) in HepG2 cells. Effects of SLCO1B1 inducers (c) and inhibitors (d) on atorvastatin and repaglinide (RE) uptake by HepG2 cells. Influences of CYP3A4 inducers and inhibitor on atorvastatin (AT) and midazolam (MI) metabolism (e). Correlations between (f) CYP3A4 activity (1-hydroxymidazolam formation), (g) SLCO1B1 activity (repaglinide uptake) and cell viability in HepG2 cells. Expressions of CYP3A4 and SLCO1B1 in HepG2 cells with CYP3A4, SLCO1B1 or dual knockdown (i,j). Effects of CYP3A4, SLCO1B1 or dual knockdown on atorvastatin hepatotoxicity (h) and ROS formation (k) in HepG2 cells. Full-length blots are presented in the Supplement. Data were represented as means ± SD (n = 4) *p < 0.05, **p < 0.01 vs. control cell, +p < 0.05, ++p < 0.01 vs. vehicle.